Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Substituting trastuzumab emtansine for adjuvant trastuzumab improved IDFS for breast cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.12.18
Views: 344

Prof Charles Geyer - Allegheny General Hospital, Pittsburgh, USA

Prof Charles Geyer gives a press conference at SABCS 2018 about the results of the phase III KATHERINE clinical trial, which found that substituting trastuzumab emtansine for adjuvant trastuzumab in improved IDFS in patients with HER2-positive early breast cancer who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab.

Watch his interview with ecancer here

Read more about this work here.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation